ArcticZymes® AS strengthens its Sales & Marketing force
ArcticZymes® is pleased to announce the hiring of Mr. Dino DiCamillo in a temporary position as worldwide Director of Sales and Marketing. DiCamillo has more than 30 years experience as a commercial and operational leader in the research and diagnostic industry and a proven track record in business development, key account strategy and management, OEM sales, and end-user marketing activities.
The commercial success of ArcticZymes® will depend on successful sales to some of the largest accounts in the molecular biology industry, and the company therefore seeks to enhance its strategic sales capabilities in the important early phase of the global commercialization. DiCamillo has been hired for a period 6-9 months.
Dino DiCamillo is currently the director of Percorso Life Sciences LLC in Plymouth Meeting, Pennsylvania, which is supporting ArcticZymes® strategic development and operations in North America. He is therefore already well acquainted with the ArcticZymes® team, product portfolio and business proposition.
“We are glad to have Dino on our team, and his unique experience in this field adds valuable strength to the organization. Our intention is to facilitate our end-users’ research by providing access to our products and technical support in an effective and productive manner,” says Jan Buch Andersen, Managing Director of ArcticZymes® AS.
For further information, please contact:
Managing director Jan Buch Andersen, tel +47 46746171
CEO Biotec Pharmacon Svein Lien, tel + 47 92289323
About ArcticZymes® AS:
ArcticZymes® AS develops, produces and sells enzymes used in molecular DNA technologies and diagnostics. The market is highly expansive, and the rapid and diversifying technological development creates a strong market demand for new and improved enzymes. More information on www.arcticzymes.com.
About Biotec Pharmacon:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The fully owned Biotec BetaGlucans AS focuses on identifying, developing and commercializing innovative products within wound treatment, cancer and gastroenterology. The company's technology is protected by a large patent portfolio covering amongst others applications of yeast beta-glucans as adjuvants in conjunction with monoclonal antibodies. The subsidiary ArcticZymes®AS aspires to become a leading supplier of novel enzymes for diagnostics and genetic research. More information on www.biotec.no.